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Reply to ‘Different outcome
variables yield different results’,
by O. Brouckaert et al.
We thank Brouckaert et al. [1] for their comments on our
paper, in which they question our ﬁnding of a lack of effect of
chemotherapy in postmenopausal patients with invasive
lobular breast cancer (ILC).
The study by von Minckwitz et al. indeed seems to indicate
that pathologic complete remission may not be a good
predictor for the ultimate prognosis in patients with ILC [2].
But the fact remains that also in this study the likelihood of a
pathologic complete response was rare (<10%) in patients with
ILC and more than twofold lower than in those with invasive
ductal cancer (IDC). And so far, we are still looking for the
biological mechanisms which could explain this lack of
response to neoadjuvant chemotherapy in patients with ILC.
For any factor to be a true confounder, it needs to be
associated with the likelihood of receiving chemotherapy as
well as with the overall survival. Unlike histological grade, for
which we have adjusted in the multivariable analysis, vascular
invasion and HER2 status have never been mentioned as
criteria for the use of chemotherapy in the Dutch treatment
guidelines, neither in patients with ILC nor in those with IDC.
The same holds true for comorbidity, frailty or other factors
that might limit general life expectancy. Although they may
have inﬂuenced the decision to use chemotherapy in the
patients observed in our study, it is very unlikely that that this
inﬂuence was dependent on the histological type of the study
and could thus explain the differences observed between ILC
and IDC with respect to the effect of chemotherapy.
We have tried to rule out the impact of the estrogen (ER) and
progesterone receptor (PR) status on our ﬁndings by restricting
our study population to patients who received hormonal
treatment, assuming that they all had a positive ER and/or PR
status. We agree with Brouckaert and colleagues that it would be
interesting to see if and to what extent the levels of ER and PR
expression are responsible for the differences in sensitivity to
chemotherapy between ILC and IDC. Currently, we are planning
such a study. A recent study of patients enrolled in the
Tamoxifen Exemestane Adjuvant Multinational trial did not
show any signiﬁcant differences between ILC and IDC when
looking at semi-quantitative ER expression levels according to
the Allred score, but this score may not be sensitive enough [3].
As we have also clearly stated in the discussion of our paper, we
are well aware of the limitations of the observational design of our
study and thus, do not dispute the view that our results need to be
validated by other studies before they can lead to a change in the
treatment of patients with ILC. We hope that our ﬁndings and the
clinical importance of the question are convincing enough to
stimulate others to provide evidence from randomized data.
W. Truin1,*, A. C. Voogd2 & R. M. H. Roumen1
1Department of Surgery, Maxima Medical Centre, Veldhoven
2Department of Epidemiology, Comprehensive Cancer Centre South (IKZ),
Eindhoven Cancer Registry, Eindhoven, The Netherlands
(*E-mail: wilfredtruin@hotmail.com)
disclosure
The authors have declared no conﬂicts of interest.
references
1. Brouckaert O, Wildiers H, Neven P. Different outcome variables yield different
results! Ann Oncol 2013; 24: 554.
2. Von Minckwitz G, Untch M, Blohmer JU et al. Deﬁnition and impact of pathologic
complete response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol 2012; 30(15): 1796–1804.
3. Van de Water W, Fontein DB, van Nes JG et al. Inﬂuence of semi-quantitative
oestrogen receptor expression on adjuvant endocrine therapy efﬁcacy in ductal and
lobular breast cancer—a TEAM study analysis. Eur J Cancer 2012 September 3
[epub ahead of print].
doi: 10.1093/annonc/mds632
Staging for distant metastases in
operable breast cancer:
a suggested expansion of the
ESMO guideline
recommendation for staging
imaging of node-negative,
hormonal receptor-negative
disease
We evaluated the impact of staging procedures to detect
asymptomatic distant metastases (DM) in the management of
women with operable invasive breast cancer (BC, entire cohort:
n = 866). Out of 472 patients with lymph node (LN)-negative
disease (pN0), DM were found in four cases (detection rate: 0.8%).
All four patients presented with established risk factors: hormone
receptor (HR)-negative status, HER2-positive status, n = 3; ‘triple-
negative’ disease, n = 1. Considering the subgroup of LN-negative
patients whose tumors showed the risk factor ‘negative HR status’
(n = 66), the detection rate of DM was 6%. The detection rates of
DM in higher pN categories were as follows: pN1:1.7%; pN2:9.5%;
pN3:13.5%. We generally support the international guidelines,
including those published by the European Society for Medical
Oncology (ESMO) which emphasize that patients with early-stage
BC do not proﬁt from radiological staging for the detection of DM
and recommend refraining from this. However, we would expand
these guidelines and propose that screening should be carried out
in node-negative patients whose tumors show established tumor-
related risk factors (e.g. HR-negative and HER2-positive status),
since in this particular subcohort, the detection rate of DM is with
6% similarly high as that of patients with four to nine positive LNs.
The incidence of detectable metastatic disease at the time of
breast cancer (BC) diagnosis is extremely small in patients with
early-stage lymph node (LN)-negative disease. Regarding the
question whether diagnostic procedures for the detection of
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potential distant metastases (DM) are appropriate and efﬁcient,
the literature deﬁned a 1% cut-off for clinical usefulness [1].
According to this, the current international guidelines for the
management of women with operable BC generally
recommend against routine use of staging imaging studies to
detect asymptomatic DM in patients who have axillary LN-
negative disease [2, 3].
Since in Switzerland many breast centers still carry out
general radiological screening for DM in all patients with
operable BC, we evaluated the impact of this procedure using
Swiss data. We analyzed data from the University Women’s
Hospital Basel (Basel, Switzerland) from a time period in
which such a general screening (chest X-ray, abdominal
ultrasound and bone scintigraphy) was still being routinely
conducted at our institution.
All invasive BC patients who underwent primary surgery
with axillary staging between 1990 and 2004 at our
institution and had no clinical symptoms indicating the
presence of DM form the basis of this study (n = 866,
Table 1, Part A). Out of 472 patients with LN-negative
disease (pN0), DM were found in four cases (detection rate:
0.8%). All four patients presented with established risk factors:
hormone receptor (HR)-negative status, HER2-positive status,
n = 3; ‘triple-negative’ disease, n = 1; Table 1, Part B.
Considering the subgroup of LN-negative patients whose
tumors showed the risk factor ‘negative HR status’ (n = 66), the
detection rate of DM was 6%. In patients who had one to
three positive LNs (pN1, n = 237), four women were found to
have DM (detection rate: 1.7%). None of these cases had
either of the risk factors ‘HR negative’ or ‘HER2 positive’.
The detection rates of DM in higher pN categories were as
follows: pN2 (4–9 positive LNs): 9.5% (8 of 84 patients); pN3
(≥10 positive LNs): 13.5% (10 of 74 patients).
conclusion
We generally support the international guidelines, including
those published by the European Society for Medical Oncology
(ESMO) which emphasize that patients with early-stage BC do
not proﬁt from radiological staging for the detection of
metastatic disease and recommend refraining from this [2].
However, we would expand these guidelines and propose that
screening should be carried out in the subgroup of node-
negative patients whose tumors show established tumor-related
risk factors (e.g. HR-negative and HER2-positive status), since
in this particular subcohort, the detection rate of DM is not
letters to the editor Annals of Oncology
Table 1. Part A: Clinicopathological features in 866 cases with operable breast cancer (1990–2004). Part B: Four patients who had node-negative disease but
had distant metastases (DM) diagnosed at the time of initial diagnosis.
Entire cohort
n = 866
pN0
n = 472 (54.5%)
pN1
n = 237 (27.4%)
pN2
n = 84 (9.7%)
pN3
n = 73 (8.4%)
Part A
Cases with DM (%) 26 (3.0) 4 (0.8) 4 (1.7) 8 (9.5) 10 (13.5)
Median age (range) 60 (26–90) 60 (26–88) 60 (28–88) 56 (32–89) 60 (30–90)
Median tumor size (mm) (range) 20 (<1–140) 16 (<1–84) 22 (5–70) 25 (6–100) 35 (11–140)
Median number of axillary LNs removed (range)a 17 (1–54) 16 (1–54) 17 (2–46) 19 (7–38) 23 (11–51)
Hormone receptor (HR) status
Known 834 447 231 83 73
positive (%) 694 (83.2) 385 (86.1) 196 (84.8) 63 (75.9) 50 (68.5)
Grading
Known 819 442 224 81 72
G3 (%) 394 (48.1) 183 (41.4) 114 (50.9) 47 (58.0) 50 (69.4)
HER2 status
Known 524 278 138 60 48
positive (%) 105 (20.0) 50 (18.0) 23 (16.7) 16 (26.7) 16 (33.3)
Part B Case 1 Case 2 Case 3 Case 4
Year of intial diagnosis 1995 2000 2000 2004
Patient’s age at initial diagnosis 54 70 78 63
Tumor size (mm) 24 18 21 30
Number of axillary LNs removed 23 7 13 1 (sentinel LN)
Site of DM HEP OSS LYM OSS
Grading 2 3 3 3
HR status Negative Negative Negative Negative
HER2 status Positive Positive Negative Positive
Outcome: died of metastatic BC Yes Yes Yes Yes
Survival time (months) 16 4 20 34
aIn 2003 a sentinel LN biopsy was established as a standard procedure.
LN: Lymph nodes; BC: breast cancer; Site of DM: HEP = hepatic; OSS = osseous; LYM = lymph nodes, excluding axilla (in the particular case reported:
supraclavicular, cervical and mediastinal LN).
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negligible. In fact, the 6% detection rate in these patients is
similar to that of patients with four to nine positive LNs.
According to current therapy guidelines, patients who have
HR-negative BC usually receive adjuvant multidrug
chemotherapy. It is exactly these patients who should have
additional diagnostic procedures carried out in order to
exclude DM and thereby conﬁrm the adjuvant situation, which
justiﬁes aggressive combination chemotherapy.
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Reply to ‘Staging for distant
metastases in operable breast
cancer: a suggested expansion
of the ESMO guideline
recommendation for staging
imaging of node-negative,
hormonal receptor-negative
disease’ by U. Gueth et al
Dr Güth et al. [1] report an analysis of postoperative staging of
patients with breast cancer in the University of Basel cohort.
Their main message is that their patients with ER-negative
apparent stage I breast cancer have a similar probability of
distant metastases as patients with apparent stage II disease.
Based on their data, it would seem logical to apply the same
protocols of staging to patients with ‘high-risk stage I’ breast
cancer.
The rationale of adjuvant therapy is the eradication of
distant metastases at a time when they are not detectable by
clinical methods. In the last decade, adjuvant therapy has
become more effective with the introduction of taxanes,
trastuzumab, and aromatase inhibitors; this implies that a
higher number of micrometastases can be eliminated by
therapy. Thus, the traditional concept of ‘cM0’ in TNM
terminology is open to question, and the naïve use of
sophisticated staging methods changes or undermines the
meaning of the term ‘adjuvant’. The threshold probability of
distant metastases above which staging procedures are
considered useful depends not only on the cost and
convenience of screening, but also on the efﬁcacy of current
therapeutic options. The conventional staging procedures such
as bone scans, chest radiographs, and abdominal ultrasound
examinations have been used in most clinical trials of adjuvant
therapy. They traditionally directed therapy by identifying
patients with advanced disease who were not amenable to
medical cure. This is not the case for other staging methods
such as the detection of epithelial cells in bone marrow
aspirates. In the context of current adjuvant therapies, it is
conceivable that overdiagnosis of distant disease by more
sensitive staging techniques including computed tomography
with positron emission tomography may not prevent
overtreatment of incurable disease but lead to undertreatment
of potentially curable patients.
The performance of most staging methods has been
evaluated only in terms of diagnostic accuracy but not in terms
of patient outcome. At present, the relative merits of different
staging methods are subject to numerous biases as is reﬂected
in the range of recommendations in different clinical
guidelines. Clinical trials investigating the value of different
staging algorithms are needed to avoid over- and
undertreatment. In this context, Dr Güth’s comments are well
taken and will be considered in the development of a future
update of the guidelines.
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